Introduction
============

*Yersinia pestis*, the infective agent of plague, has caused social devastation on a scale unmatched by any other infectious agent. Although it is not a major public health problem now, *Yersinia pestis* still infects rodent populations in large endemic zones, and there are cases of human plague reported annually. After inoculation by a flea bite, *Y. pestis* multiplies in the lymph nodes and finally overwhelms its rodent or human host with massive growth. The closely related food-borne pathogens *Yersinia pseudotuberculosis* and *Yersinia enterocolitica* penetrate into the tissues of their host by crossing the intestinal barrier at the lymphoid follicles called Peyer\'s patches and then multiply in the abdominal lymphoid tissues.

Pathogenic *Yersinia* species share the Yop virulon, encoded on a 70-kb plasmid, which is the core of the *Yersinia* pathogenicity machinery designed for close combat with cells of the immune system ([Fig. 1](#fig1){ref-type="fig"}). The Yop virulon comprises both the Yop effector proteins and the proteins necessary for injecting them into host cells. The injected Yops perturb the dynamics of the cytoskeleton, disrupting phagocytosis, and block the production of proinflammatory cytokines, thus favoring the survival of the invading *Yersinia*.

![**Secretion of Yops by the Ysc injectisome and translocation across the target cell membrane.** When *Yersinia* are placed at 37°C in a rich environment, the Ysc injectisome is installed and a stock of Yop proteins is synthesized. During their intrabacterial stage, some Yops are capped with their specific Syc chaperone. Upon contact with a eukaryotic target cell, the adhesins YadA or Inv interact with integrins and the bacterium docks at the cell\'s surface. Then, the secretion channel opens and Yops are exported. YopB and YopD form a pore in the target cell plasma membrane, and the effector Yops are translocated across this membrane into the eukaryotic cell cytosol. YopM migrates to the nucleus. EM, outer membrane; P, peptidoglycen; IM, plasma membrane.](200205077f1){#fig1}

The Yop virulon is an archetype of the type III secretion systems (TTSSs)[\*](#fn1){ref-type="fn"} now identified in more than a dozen major animal or plant pathogens ([@bib16]; [@bib13]). Some of these, including *Salmonella enterica*, have two TTSSs, both of which are essential for pathogenicity and come into play at different stages of infection. One is required for the initial interaction of *S. enterica* with intestinal epithelial cells, whereas the other is expressed only after *S. enterica* has gained access to host cells and is required for systemic infection ([@bib27]). A homologue of the first *S. enterica* TTSS is found in *Shigella flexneri* where it also functions to promote invasion of epithelial cells ([@bib57]). In enteropathogenic *Escherichia coli*, a different TTSS remodels the cytoskeleton of enterocytes, leading to the formation of a pedestal of unknown function underneath the bacterium ([@bib14]).

In this mini-review, I will consider the Yop virulon as a model of type III secretion but will draw on other examples when their molecular description has gone beyond that of *Yersenia*. The virulon consists of three basic components: the Ysc injectisome, spanning the bacterial membranes, the Yop effectors, and the Yop translocators, needed to deliver the effectors across the eukaryotic plasma membrane.

The injection of bacterial proteins into a eukaryotic cell
==========================================================

The Ysc injectisome.
--------------------

Before contact with eukaryotic target cells, *Yersinia* bacteria incubated at the temperature of their host build several syringe-like organelles at their surface ([Fig. 1](#fig1){ref-type="fig"}). These organelles, called the Ysc injectisome, are protein pumps spanning the peptidoglycan layer and the two bacterial membranes topped by a stiff needle-like structure protruding outside the bacterium. The whole organelle comprises 27 proteins. The internal part contains ∼10 proteins, which have counterparts in the basal body of the flagellum, indicating that the two organelles have a common evolutionary origin. An essential part of the pump is an ATPase resembling the α and β subunits of F~0~F~1~ proton translocase. The external part of the injectisome, which spans the bacterial outer membrane, is not related to the flagellum and presumably has a different evolutionary origin. It is a homomultimeric ring-shaped structure with a central pore of ∼50 Å ([@bib35]). The monomer is related to the protein that filamentous phage insert into the bacterial outer membrane to allow their extrusion. The Ysc injectisome ends with a 60--80-nm-long and 6--7-nm-wide needle formed by the polymerization of monomers of the 6-kD YscF protein that are secreted by the Ysc apparatus itself ([@bib31]). Like the length of the hook of the flagellum ([@bib43]), the length of the needle is genetically controlled (L. Journet, and P. Broz, personal communications; unpublished data).

More is known about the needle complex of the TTSS that is common to *S. enterica* and *S. flexneri* ([@bib34]; [@bib36]; [@bib9]). The base appears as two pairs of rings that are anchored to the inner and outer membranes of the bacterial envelope and are joined by a central rod. Not surprisingly, this architecture resembles that of the flagellar hook--basal body complex. Protruding outward from the base is the needle itself with a length of ∼8 nm and a central diameter of 2--3 nm. Enteropathogenic *Escherichia coli* possess a similar complex, but in this case the needle extends as a larger filament of 10--12 nm diameter and a variable length of 75--260 nm ([@bib18]).

It is generally assumed that the injectisome serves as a hollow conduit, allowing the exported proteins to travel across the two membranes and the peptidoglycan barrier in one step. If so, they have to travel at least partially unfolded because the internal diameter of the needle would not allow the passage of fully folded globular proteins. The injectisome, as described here, is sufficient for bacteria to secrete Yops into their environment but it is not sufficient for the injection of Yops into target animal cells (see below).

Regulation of Yop secretion.
----------------------------

Effector Yops destined for secretion through the injectisome have no classical signal sequence ([@bib42]). Nevertheless, a minimum of 15 residues at the NH~2~ terminus are necessary for Yop secretion ([@bib64]; [@bib1]). No sequence similarity with other known proteins could be detected in this region, and systematic mutagenesis of the secretion signal ([@bib1], [@bib2]) led to doubts about the proteinaceous nature of this signal. Indeed, no point mutation was identified that specifically abolished secretion of YopE, YopN, or YopQ, and moreover, some frameshift mutations that completely altered the peptide sequences of the signals also failed to prevent secretion. [@bib1]([@bib2]) concluded from these observations that the signal for secretion of these Yops could be in the 5′ end of the messenger RNA and that Yop secretion may be regulated at the level of translation. Translation of *yop* mRNA might be inhibited either by its own structure or as a result of its binding to other regulatory elements ([@bib1], [@bib2]). If this is correct, one would not expect to detect Yop proteins inside bacteria in conditions that are not permissive for secretion. However, although this may be true for some Yops ([@bib2]), it is not true for others, such as YopE ([@bib8]), implying that regulation of secretion is at least partially posttranslational.

Kinetic studies also raise questions about the mRNA signal hypothesis, since the bacterial antiphagocytic response needs to be extremely fast. Recently, [@bib39] showed that secretion of YopE was not impaired after the first 11 codons of YopE were mutated to modify the mRNA but not the amino acid sequence. This suggested that it is indeed the NH~2~-terminus of YopE protein and not the 5′ end of *yopE* mRNA that serves as a targeting signal. They proposed that an amphipathic peptide helix is recognized by the injectisome. Thus, although the nature of the signal remains controversial ([@bib50]), it is currently thought that the signal for initial secretion is likely to be in the protein rather than in mRNA. However, this does not preclude the possibility that secretion may be cotranslational at a later stage of infection.

Keeping the Yops fit for secretion.
-----------------------------------

Secretion of some Yops requires the presence of small cytosolic chaperones of a family called the Syc proteins (for specific Yop chaperone) ([@bib69]; [@bib70]). These are small acidic proteins with little or no sequence similarity between them but with a common, putative COOH-terminal amphiphilic α-helix. They bear no sequence or functional resemblance to ATP-dependent chaperones, such as heat shock protein 70 (Hsp70). They only bind only to a specific partner Yop, and in their absence Yop secretion is severely reduced, if not abolished. In general, Syc proteins are encoded by a gene located beside the gene encoding the protein they serve.

The exact function of the Syc proteins remains mysterious. Hans Wolf-Watz and colleagues ([@bib39]) showed recently that the immediate injection of stored YopE requires the SycE chaperone, whereas long term cotranslational delivery of YopE does not. This observation suggests that SycE maintains preformed, stored YopE in a "secretion-competent" (presumably unfolded or partially folded) state. Crystal structure analyses of the chaperone-binding domain of YopE ([@bib5]) and SptP from *S. enterica* ([@bib65]) bound to their respective chaperones revealed striking stereochemical conservation, despite the absence of sequence similarity, indicative of a universal mode of interaction between TTSS chaperones and effectors. However, there is no agreement on the interpretation of these findings: although it is proposed that the chaperone of SptP maintains the whole protein in a partially unfolded, secretion-competent state, it appears that the SycE--YopE complex is catalytically active and thus folded. At this stage, we are therefore left with at least two hypotheses regarding the role of TTSS chaperones: either they prevent folding ([@bib65]) or they provide a three-dimensional "helper" secretion signal ([@bib5]), perhaps orchestrating secrection of effectors in a defined order as suggested by other experiments ([@bib12]; [@bib71]). An additional intriguing question regarding these chaperones is which protein strips the chaperone off of its partner as it enters the injectisome channel?

Preparing to fire.
------------------

Once bacteria reach a temperature of 37°C, the injectisomes are assembled and a stock of intracellular Yops is synthesized. However, the secretion channel remains closed, and feedback inhibition prevents a deleterious accumulation of Yops ([@bib17]). This retrocontrol, which involves several Yops and chaperones, is very complex and still not fully understood ([@bib26]). The idea that some intrabacterial chaperones participate in the feedback regulatory mechanism is particularly appealing. Indeed, the concentration of a specific chaperone is directly linked to the rate of secretion of its partner Yop. This concept has been nicely documented in TTSS from *S. enterica* ([@bib19]) and *Shigella flexneri* ([@bib40]).

Upon close contact with a target cell, some injectisome channels become unplugged and secretion starts. The required contact is not achieved by the needle itself but by the interaction between bacterial outer membrane proteins called adhesins and integrins at the surface of a target cell. In the case of phagocytes, the adhesins are dispensable because phagocytic receptors provide the necessary intimate contact. [@bib48] provided a nice visual demonstration of the contact dependency phenomenon. By expressing luciferase under control of a *yop* promoter, these authors showed that active transcription of *yop* genes is indeed limited to bacteria that are in close contact with eukaryotic cells.

Whether lipids or specific host protein receptors are involved in regulating secretion is not known, at least in the case of *Yersinia*. It seems unlikely that protein receptors are involved, since Yops are injected into every cell type to which *Yersinia* can dock. A few mutants can secrete Yops in a contact-independent manner, indicating that some proteins constitute one or more plugs along the channel. One of these proteins is YopN, which is secreted but is not a translocator or effector protein ([@bib25]; [@bib11]; [@bib15]). So far, no interaction between YopN and any cellular surface component has been reported.

Translocation of effectors across animal cell membranes.
--------------------------------------------------------

Purified secreted effector Yops have no cytotoxic effect on cultured cells unless they are microinjected into them ([@bib53]). This suggested that Yop effectors are injected into the eukaryotic cell cytosol by extracellular adhering bacteria. This hypothesis was demonstrated by confocal laser scanning microscopy ([@bib54]) and by following the accumulation of cAMP in eukaryotic cells infected with bacteria expressing a Yop--calmodulin-dependent adenylate cyclase hybrid ([@bib63]). Translocation of the Yop effectors into the host cell requires the secretion of the translocator Yops--YopB, YopD, and LcrV ([@bib54]; [@bib63]; [@bib47]; [@bib11]; [@bib49]). YopB and YopD have hydrophobic domains, suggesting that they could act as transmembrane proteins ([@bib54]; [@bib63]; [@bib11]). In agreement with this, the membrane of cells infected with a mutant *Y. enterocolitica* making translocators but not effectors becomes permeable to small dyes ([@bib44]). If the cells are preloaded with a low molecular weight fluorescent marker before the infection, they release the fluorescent marker but not cytosolic proteins, indicating that there is no membrane lysis but rather insertion of a small pore (diameter 16--23 Å) into the cell plasma membrane ([@bib44]). In addition, artificial liposomes that have been incubated with *Y. enterocolitica* producing YopB, YopD, and LcrV contain channels detectable by electrophysiology ([@bib66]). Since these pores are only detectable in the absence of secreted Yop effectors, it is generally believed that trafficking Yop effectors obstruct the pore. Clearly, if the pore formers are not present at the tip of the needle before contact, they need to be the first Yop proteins to be secreted immediately after contact is established with a target cell. However, the hierarchy of secretion remains an open question.

The fact that the Ysc secretion apparatus ends up with a long needle protruding from the bacterium raises the question of the relationship between the needle and the pore formers. Because the injection process requires the very tight adhesin-mediated contact, the needle must either retract, break down, or pierce the target cell membrane as suggested by some EM observations ([@bib31]). It is possible that YopB, YopD, and LcrV destabilize the host cell membrane, enabling the needle to pierce it, driven by the pressure that gradually builds up as a result of the increased docking of the bacterium at the cell surface. Whether this happens or not, there are good arguments to believe that the Yop effectors are guided in a continuous channel from the bacterial cytosol to the target cell cytosol. Indeed, the minimal signal required for their recognition by the Ysc secretion apparatus is sufficient to ensure translocation across the eukaryotic cell plasma membrane.

Intracellular action of the Yop effectors
=========================================

Inhibition of phagocytosis by YopH, YopE, YopT, and YopO/YpkA.
--------------------------------------------------------------

Once inside the eukaryotic cell, the Yop effectors inhibit signaling cascades and block the ability of the cell to respond to infection. Out of six effectors identified so far, four inhibit cytoskeleton dynamics (YopH, YopE, YopT, and YopO/YpkA). By doing so, they contribute to the strong resistance of pathogenic *Yersinia* to phagocytosis by macrophages ([Fig. 2](#fig2){ref-type="fig"}) ([@bib52]; [@bib8]; [@bib24]; [@bib29]) and polymorphonuclear leukocytes ([@bib67]; [@bib4]; [@bib29]). *Y. enterocolitica* lacking only one of these four Yops are more efficiently phagocytosed by polymorphonuclear leukocytes and by J774 cultured macrophages, indicating that there is no redundancy between the Yops but rather synergy ([@bib29]).

![**Antiphagocytic action of the Yops.** Upon contact with a phagocyte receptor (R), a signaling cascade is triggered and GTP-bound Rho family members (RhoA, Rac-1, Cdc42) promote actin polymerization. YopE, acting as a GAP, down-regulates Rac-1, Cdc42, and RhoA. The YopT protease cleaves the COOH terminus of RhoA, Rac, and Cdc42, liberating them from the plasma membrane. The YpkA/YopO kinase becomes autophosphorylated upon contact with actin and interacts with RhoA and Rac-1. The PTPase YopH is targeted to focal adhesions and to other protein complexes where it dephosphorylates proteins such as the focal adhesion kinase (Fak), p130Cas, and SKAP-HOM.](200205077f2){#fig2}

The effector YopH is among the most powerful phosphotyrosine phosphatases (PTPase) known ([@bib73]) and also acts to inhibit phagocytosis. When injected into J774 macrophages, YopH dephosphorylates p130^Cas^ and disrupts focal adhesions ([@bib30]). It also dephosphorylates the Fyn-binding protein Fyb ([@bib30]) and the scaffolding protein SKAP-HOM. These proteins interact with each other and become tyrosine phosphorylated in response to macrophage adhesion ([@bib7]).

The action of YopH against macrophages is extremely fast. When a macrophage contacts *Y. pseudotuberculosis*, Fyb and SKAP-HOM become phosphorylated within 30 s. Within 2 min, YopH-mediated dephosphorylation is visible already ([@bib3]). YopH also protects *Yersinia* against phagocytosis by polymorphonuclear leukocytes ([@bib67]; [@bib29]). In this case, the mechanism of antiphagocytosis has not been investigated as well as in macrophages, but YopH has been shown to abrogate calcium signaling in these cells within seconds ([@bib4]).

The three other Yop effectors counteracting phagocytosis, YopE, YopT, and YpkA/YopO, act on monomeric GTPases of the Rho family, which are known to control the dynamics of the cytoskeleton. YopE ([@bib52]) acts as a GTPase-activating protein (GAP), switching RhoA, Rac1, and Cdc42 to the inactive state by accelerating GTP hydrolysis ([@bib6]; [@bib68]). Rho family members are anchored to the inner side of the cell\'s plasma membrane by a prenyl group attached at their COOH terminus, and attachment is essential for their function (for a review see [@bib51]). YopT ([@bib32]) has been shown recently to be a cysteine protease that cleaves Rho, Rac, and Cdc42 near their COOH terminus, releasing them from the membrane ([@bib61]). YpkA (for *Yersinia* protein kinase A) is an 80-kD autophosphorylating serine-threonine kinase ([@bib28]) that shows some sequence and structural similarity to RhoA-binding kinases ([@bib22]). YpkA is activated by actin binding ([@bib33]), and actin can also function as an in vitro substrate of the kinase. Although binding of YpkA/YopO to actin and to RhoA and Rac-1 is clearly relevant in the context of phagocytosis inhibition, the kinase target and the exact mode of action of YpkA/YopO remain unknown.

Blockade of the immune system by YopP/J and by YopH.
----------------------------------------------------

Yop effectors also promote the intracellular survival of *Yersinia* by counteracting the normal proinflammatory response of cells to infection ([Fig. 3](#fig3){ref-type="fig"}). YopJ (YopP in *Y. enterocolitica*) reduces the release of TNF-α ([@bib10]) by macrophages and of IL-8 by epithelial ([@bib60]) and endothelial cells ([@bib21]). It also reduces the presentation of adhesion molecules ICAM-1 and E-selectin at the surface of endothelial cells ([@bib21]) and presumably reduces neutrophil recruitment to the site of infection. All of these events result from the inhibition of activation of NF-κB, a transcription factor known to be of central importance in the onset of inflammation ([@bib10]; [@bib60]). YopP/YopJ inhibits IKKβ, a kinase that phosphorylates I[k]{.smallcaps}B, the inhibitor of NF-κB ([@bib45]). By preventing phosphorylation of IκB, YopP/YopJ prevents its degradation and thus prevents the translocation of NF-κB to the nucleus.

![**Down-regulation of the inflammatory response.** YopP binds and blocks the I[k]{.smallcaps}B kinase β (IKKβ), which inhibits the phosphorylation and degradation of I[k]{.smallcaps}B, the inhibitor of NF-kB. This in turn prevents the migration of the transcription factor NF-κB to the nucleus. The absence of NF-κB in the nucleus prevents transcription of antiapoptotic genes and several proinflammatory genes including the TNF-α gene. YopP also blocks the MKKs, inhibiting the activation of MAPK, which abrogates activation of CREB, another transcription factor involved in the immune response. YopP induces apoptosis in macrophages, either directly by acting upstream of Bid or indirectly by blocking the synthesis of NF-κB--dependent antiapoptotic factors. Yop H inhibits the production of monocyte chemoattractant protein 1 (MCP-1) by dephosphorylating key players in the phosphatidylinositol 3-kinase/Akt pathway.](200205077f3){#fig3}

Macrophages infected with *Yersinia* secreting YopP/YopJ also lack the usual activation of mitogen-activated protein kinases (MAPKs), c-jun--N-terminal kinase, p38, and extracellular signal-regulated kinase 1 and 2 ([@bib55]; [@bib10]) due to the inhibition of upstream MAPK kinases (MKKs) ([@bib45]). Inhibition of the MAPK pathways abrogates phosphorylation of CREB, another transcription factor involved in the immune response ([@bib41]). Last but not least, YopP/YopJ induces apoptosis of macrophages but not of other cell types ([@bib20]). It is not clear yet whether apoptosis results from a YopP-induced early cell death signal or from the YopP-induced loss of NF-κB activity known to protect cells from apoptosis ([@bib56]). Recently, it was suggested that YopJ/P is a cysteine protease, possibly a SUMO protease (SUMO are ubiquitin-like proteins that are involved in posttranslational modification) ([@bib46]). However, this result is not easy to link to the previous findings that YopJ/P interacts with the MKKs and IKKβ pathways, preventing their phosphorylation.

Recent observations have shown that YopH also contributes to the down-regulation of the inflammatory response. Indeed, YopH exerts an inhibitory effect on the synthesis of the monocyte chemoattractant protein 1, a chemokine involved in the recruitment of other macrophages to the sites of infection ([@bib58]). In the same vein, [@bib72] observed that T and B cells transiently exposed to *Y. pseudotuberculosis* are impaired in their ability to be activated through their antigen receptors. These events result from the inhibition by YopH of early phosphorylation events ([@bib72]) and of the subsequent activation of the phosphatidylinositol 3-kinase pathway ([@bib58]). Thus, YopH not only contributes to *Yersinia\'s* evasion of the innate immune response by inhibiting phagocytosis, but it also incapacitates the host adaptive immune response.

The YopM enigma.
----------------

YopM is a strongly acidic protein containing 13--20 repeats of a 19-residue leucine-rich repeated motive ([@bib37]) folded in a crescent shape ([@bib23]). Although YopM is an important Yop effector in mouse infection ([@bib38]; [@bib11]), its function has not yet been defined yet. It has been shown to migrate to the nucleus of target cells by means of a vesicle-associated pathway ([@bib62]), and recent microarray experiments ([@bib59]) indicate that it influences gene transcription, leading to new working hypotheses now being tested.

Conclusion
==========

The Ysc--Yop system is a powerful integrated weapon that combines an organelle-like secretion apparatus and a set of protein effectors. Although the former is typically prokaryotic and related to the bacterial flagellum, the latter has probably been taken up from eukaryotic cells. Indeed, Yop effectors have more sequence similarity to eukaryotic proteins than to bacterial house-keeping proteins, and they act in a physiological way on targets that do not exist in bacteria. The most remarkable element may not be how the complex nanosyringe of the injectisome has evolved but rather how the effectors have been recruited. If it is easily conceivable that eukaryotic DNA was taken up by bacteria during evolution, it is more difficult to understand how these genes have been selected for their role in TTS. Indeed, to function they needed to integrate in the bacterial genome in such a way that they received a type III secretion signal and became expressed at the right time. This may have occurred in different steps and involved different bacterial hosts.

The Ysc--Yop system makes use of half a dozen effectors and at least five of them work in a cooperative way to incapacitate phagocytosis and inflammation. Moreover, some of them, like YopH, even play a role in both events. This concentration of effort on two key events is a sign of extreme sophistication. The recent elucidation of the targets of the Yops not only leads to a better understanding of the mechanism of *Yersinia* infection but also provides valuable insights into the intracellular signaling response to infection.

Although our understanding of the TTS system is becoming more coherent, many intriguing questions remain. In particular, by what mechanism does contact trigger secretion? Is there a hierarchy of secretion, and how is it orchestrated? How is the pore assembled, and what is its role in relation to the needle? Among the effectors, what is the function of YopM? A complete understanding of the complex intrabacterial regulatory network that orchestrates the attack will still require much concerted effort.
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